Vanguard (LGND) reports 0 shares after internal realignment (03/27/2026)

Rhea-AI Filing Summary

Ligand Pharmaceuticals Inc — The Vanguard Group filed Amendment No. 11 to a Schedule 13G/A reporting that, after an internal realignment, it reports 0 shares beneficially owned and 0% of the class of Common Stock as of the filing. The filing explains certain Vanguard subsidiaries now report separately in reliance on SEC Release No. 34-39538 and that Vanguard Inc. no longer is deemed to have beneficial ownership of securities held by those subsidiaries. The form lists Vanguard's address and is signed by Ashley Grim, Head of Global Fund Administration, dated 03/27/2026.

Insights

Institutional Ownership Analyst

Routine disaggregation left Vanguard with no reported beneficial ownership.

The filing documents an internal reorganization within The Vanguard Group that caused certain subsidiaries to report holdings separately under SEC Release No. 34-39538. The Schedule 13G/A shows 0 shares and 0% ownership of Ligand common stock.

Timing and mechanics are stated: the amendment is dated 03/27/2026. Subsequent filings by the disaggregated subsidiaries may list holdings; this filing itself reports no ownership for the parent entity.

Corporate Governance Specialist

Administrative realignment, not an economic trade.

The statement cites SEC Release No. 34-39538 to justify separate reporting by subsidiaries; it is an administrative disclosure rather than a purchase or sale by Vanguard. The filing lists the issuer address and Vanguard's business address for traceability.

Investor relevance is limited: ownership for the parent entity is 0%; investors should consult filings from the named subsidiaries for any disclosed positions.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 11)

Ligand Pharmaceuticals Inc

(Name of Issuer)

Common Stock

(Title of Class of Securities)

53220K504

(CUSIP Number)

03/13/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

schemaVersion:

SCHEDULE 13G

CUSIP Number(s): 53220K504

1

Names of Reporting Persons

The Vanguard Group

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

PENNSYLVANIA

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

0.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

0 %

12

Type of Reporting Person (See Instructions)

IA

Comment for Type of Reporting Person: On January 12, 2026, The Vanguard Group, Inc. went through an internal realignment. In accordance with SEC Release No. 34-39538 (January 12, 1998), certain subsidiaries or business divisions of subsidiaries of The Vanguard Group, Inc., that formerly had, or were deemed to have, beneficial ownership with The Vanguard Group, Inc., will report beneficial ownership separately (on a disaggregated basis) from The Vanguard Group, Inc. in reliance on such release. These subsidiaries and/or business divisions pursue the same investment strategies as previously pursued by The Vanguard Group, Inc. prior to the realignment. Further in accordance with SEC Release No. 34-39538 (January 12, 1998), The Vanguard Group, Inc. no longer has, or is deemed to have, beneficial ownership over securities beneficially owned by such subsidiaries and/or business divisions.

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Ligand Pharmaceuticals Inc
(b)	Address of issuer's principal executive offices: 3911 Sorrento Valley Blvd, Suite 110, San Diego, CA, 92121
Item 2.
(a)	Name of person filing: The Vanguard Group
(b)	Address or principal business office or, if none, residence: 100 Vanguard Blvd.,, Malvern, PA, 19355
(c)	Citizenship: PA
(d)	Title of class of securities: Common Stock
(e)	CUSIP No.:
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 0
(b)	Percent of class: 0 %
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 0
	(ii) Shared power to vote or to direct the vote: 0
	(iii) Sole power to dispose or to direct the disposition of: 0
	(iv) Shared power to dispose or to direct the disposition of: 0
Item 5.	Ownership of 5 Percent or Less of a Class.
	Ownership of 5 percent or less of a class
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required. The Vanguard Group, including investment companies registered under the Investment Company Act of 1940 and other managed accounts, have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the securities reported herein.No one other person's interest in the securities reported herein is more than 5%.
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

The Vanguard Group

Signature:	Ashley Grim
Name/Title:	Head of Global Fund Administration
Date:	03/27/2026

FAQ

What does Vanguard report for LGND ownership in this Schedule 13G/A?

The Vanguard Group reports 0% ownership and 0 shares beneficially owned. The amendment states Vanguard no longer is deemed to beneficially own securities held by certain subsidiaries after an internal realignment under SEC Release No. 34-39538.

Why does Vanguard report zero ownership for LGND on this amendment?

Because of an internal realignment effective January 12, 2026. The filing explains certain subsidiaries now report separately in reliance on SEC Release No. 34-39538, and Vanguard Inc. is no longer deemed to own those securities.

Who signed the Schedule 13G/A for Vanguard on behalf of LGND reporting?

The filing is signed by Ashley Grim, Head of Global Fund Administration. The signature block shows the representative signed and dated the amendment on 03/27/2026.

Does this filing indicate any trades in Ligand Pharmaceuticals (LGND)?

No trades are reported in this amendment. The form is an ownership disclosure reflecting reporting structure changes; it lists 0 shares and 0% ownership for the reporting entity.

Where is The Vanguard Group's principal business address listed in the filing?

The Vanguard Group's address is listed as 100 Vanguard Blvd., Malvern, PA, 19355. The Schedule 13G/A includes the filer’s principal business office for identification purposes.